Lv2
182 积分 2022-07-11 加入
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
26天前
已完结
Tumor intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer
1个月前
已完结
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer
1个月前
已完结
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
1个月前
已完结
Optimal Systemic Treatment and Real-World Clinical Application of ctDNA in Patients with Metastatic HER2-Mutant Lung Cancer
1个月前
已完结
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
1个月前
已完结
Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
1个月前
已完结
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
2个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Oesophageal cancer
2个月前
已完结
皖公网安备34019202002308
